Cargando…

Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients

Hepatitis B virus (HBV) RNA may independently predict virological and serological response. This study aimed to compare dynamic changes in serum HBV RNA levels and HBV quasispecies evolution patterns between entecavir and pegylated-interferon mono-treatment in chronic hepatitis B patients and to det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xiao-qi, Wang, Ming-jie, Yu, De-min, Chen, Pei-zhan, Zhu, Ming-yu, Huang, Wei, Han, Yue, Gong, Qi-ming, Zhang, Xin-xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Virology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448659/ https://www.ncbi.nlm.nih.gov/pubmed/32554476 http://dx.doi.org/10.1128/JCM.00075-20

Ejemplares similares

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
por: Melendez-Mena, Daniel, et al.
Publicado: (2021)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma
por: Petruzziello, Arnolfo
Publicado: (2018)

A systematic study of Tupaia as a model for human acute hepatitis B infection
por: LI, Jun, et al.
Publicado: (2021)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients
por: Zhu, Ming‐Yu, et al.
Publicado: (2018)

Characteristics of CpG Islands and their quasispecies of full-length hepatitis B virus genomes from patients at different phases of infection
por: Xue, Yuan, et al.
Publicado: (2016)

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy
por: Cao, Weihua, et al.
Publicado: (2021)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Serological evidence of hepatitis A, B, and C virus infection in older adults in Khon Kaen, Thailand and the estimated rates of chronic hepatitis B and C virus infection in Thais, 2017
por: Posuwan, Nawarat, et al.
Publicado: (2019)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Determining the Actual Prevalence of Hepatitis B in Khyber Pakhtunkhwa-Pakistan: A Meta-Analysis
por: Khan, Najeeb Ullah, et al.
Publicado: (2018)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
por: Jun, Dae Won, et al.
Publicado: (2018)

Hepatitis B virus (HBV) codon adapts well to the gene expression profile of liver cancer: an evolutionary explanation for HBV’s oncogenic role
por: Yu, Chunpeng, et al.
Publicado: (2022)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection
por: Godoy, Cristina, et al.
Publicado: (2019)

Fibroblast Growth Factor 11 Inhibits Hepatitis B Virus Gene Expression Through FXRα Suppression
por: Seong, Mi So, et al.
Publicado: (2023)

Serum HBV pregenomic RNA exhibited opposite associations with NK(dim) and NK(bright) cell immunity in treatment-naïve chronic hepatitis B patients
por: Gu, Yurong, et al.
Publicado: (2021)

Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan
por: Ababneh, Nidaa A., et al.
Publicado: (2019)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Hepatitis E virus neutralization by porcine serum antibodies
por: Gremmel, Nele, et al.
Publicado: (2023)

Effects of Entecavir on Hepatitis B Virus Covalently Closed Circular DNA in Hepatitis B e Antigen-Positive Patients with Hepatitis B
por: Shi, Ming, et al.
Publicado: (2015)

Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing
por: Fu, Ya, et al.
Publicado: (2019)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
por: Yoshida, Kanako, et al.
Publicado: (2021)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
por: Vasconcelos, Joana, et al.
Publicado: (2022)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Severe Acute Hepatitis B Treated With Entecavir.
por: De Socio, Giuseppe Vittorio Luigi, et al.
Publicado: (2011)

Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B
por: Jin, Xi, et al.
Publicado: (2012)

Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?
por: López-Martínez, Rosa, et al.
Publicado: (2019)

A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection
por: Hsiao, Shun-Wen, et al.
Publicado: (2022)

Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant
por: Xue, Yuan, et al.
Publicado: (2017)

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C
por: Ding, Yan-Hua, et al.
Publicado: (2017)

Nationwide survey of hepatitis E virus infection among wildlife in Japan
por: MENDOZA, Milagros Virhuez, et al.
Publicado: (2022)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_78khqkkb64aalmsborki2bdbl0